郝南烟
Lv4
580 积分
2021-09-22 加入
-
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non–Small-Cell Lung Cancer
1个月前
已完结
-
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
-
CNS complications of radiotherapy and chemotherapy
1个月前
已完结
-
Tumor-associated edema in brain cancer patients: pathogenesis and management
1个月前
已完结
-
Tumor-associated edema in brain cancer patients: pathogenesis and management
1个月前
已关闭
-
非小细胞肺癌肝转移免疫微环境及未来干预策略
1个月前
已关闭
-
Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors
1个月前
已完结
-
The significance of co-mutations in egfr-mutated non-small cell lung cancer: optimizing the efficacy of targeted therapies?
1个月前
已完结
-
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study
2个月前
已完结
-
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
2个月前
已完结